E Watertown, Massachusetts Clinical Trials

A listing of E Watertown, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 128 clinical trials
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

Brigham and Women's Hospital
 (4.5 away) Contact site
  • 0 views
  • 07 Jun, 2021
  • +3 other locations
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or maximum administered dose (MAD) …

Massachusetts General Hospital
 (6.0 away) Contact site
  • 0 views
  • 07 May, 2021
  • +5 other locations
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for …

BostonSight
 (5.5 away) Contact site
  • 0 views
  • 28 Jul, 2021
  • 1 location
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Boston Children's Hospital
 (5.2 away) Contact site
  • 152 views
  • 13 Apr, 2021
  • +11 other locations
Safety and Tolerability of hRPC in Retinitis Pigmentosa

hRPC is a cell therapy for retinitis pigmentosa. This is a first-in-human, dose escalation study in which participants with retinitis pigmentosa will receive a single subretinal injection of hRPC cells in one eye to evaluate safety and tolerability. Participants will be followed for two years to evaluate the safety and …

diabetes
genetic analysis
other disease
genetic testing
Massachusetts Eye and Ear Infirmary
 (6.0 away) Contact site
  • 0 views
  • 20 Jul, 2021
  • +4 other locations
Proton or Photon RT for Retroperitoneal Sarcomas

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies. "Investigational" means that the intervention is still being studied and that …

Dana-Farber Cancer Institute
 (5.2 away) Contact site
  • 2 views
  • 25 Jan, 2021
  • +9 other locations
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Boston Children's Hospital
 (5.2 away) Contact site
  • 0 views
  • 15 Apr, 2021
  • +15 other locations
Safety Tolerability Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

Dana-Farber Cancer Institute
 (5.2 away) Contact site
  • 15 views
  • 01 Aug, 2021
  • +20 other locations
AXER-204 in Participants With Chronic Spinal Cord Injury

This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204 …

Spaulding Rehabilitation
 (6.0 away) Contact site
  • 200 views
  • 02 Jun, 2021
  • +7 other locations
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for …

KRAS
solid tumor
Massachusetts General Hospital Cancer Center
 (6.0 away) Contact site
  • 0 views
  • 01 Jul, 2021
  • +14 other locations